<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207424</url>
  </required_header>
  <id_info>
    <org_study_id>19-005</org_study_id>
    <nct_id>NCT04207424</nct_id>
  </id_info>
  <brief_title>Embolization of Arterial Gastric Supply in Obesity</brief_title>
  <acronym>Embargo</acronym>
  <official_title>EMbolisation Bariatrique de l'ARcade Gastro-épiploïque Chez Les Patients Obèses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IHU Strasbourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IHU Strasbourg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess safety and efficacy of bariatric embolization of the
      gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles,
      for patients with morbid obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is now an epidemic in the developed and developing world. Medical management is
      ineffective at population level. Metabolic surgery has been shown to be effective in
      achieving weight loss and controlling associated conditions. However, surgery is invasive and
      has associated complications. Furthermore, not every patient is interested in or eligible for
      surgery.

      Bariatric gastric embolization recently emerged as a promising minimally invasive alternative
      to open bariatric surgery. Data from several initial pilot clinical trials suggests that
      gastric embolization is safe and can induce weight loss.

      Previous studies have concentrated on left gastric artery embolization as the primary target
      vessel because it supplies the largest portion of the fundus. However, it may be desirable to
      target a different artery, specifically the left gastroepiploic which also supplies the
      fundus. The left gastric artery is spared in bariatric surgery because it supplies the
      residual pouch after the surgery. Embolization of the left gastric artery may result in worse
      healing in the event of follow-up surgery potentially excluding people should they
      subsequently want it or become eligible.

      This study aims to assess safety and efficacy of bariatric embolization of the
      gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles,
      for patients with morbid obesity.

      The target population consists of adult, morbidly obese patients with contraindication for
      bariatric surgery. Patients included in the study will be followed up for 12 months post
      bariatric embolization. The primary end point is procedural safety, defined as number and
      severity of adverse events occurring during the study period. Secondary end points include
      weight loss, evolution of weight and thigh circumferences, evolution of serum ghrelin levels
      and evolution of quality of life indexes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>7 days post embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 month post embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>3 months post embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months post embolization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 months post embolization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Evaluations scheduled at 7 days, 1 month, 3 months, 6 months and 12 months post embolization</time_frame>
    <description>Weight loss expressed in percentage of total weight loss (%TWL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abdominal circumference</measure>
    <time_frame>Evaluations scheduled at 1 month, 3 months, 6 months and 12 months post embolization</time_frame>
    <description>Measurement of abdominal circumference in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thigh circumferences</measure>
    <time_frame>Evaluations scheduled at 1 month, 3 months, 6 months and 12 months post embolization</time_frame>
    <description>Measurement of thigh circumferences in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ghrelinemia</measure>
    <time_frame>Evaluations scheduled at 1 month, 3 months, 6 months and 12 months post embolization</time_frame>
    <description>Measurement of serum ghrelin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>Evaluations scheduled at 7 days, 1 month, 3 months, 6 months and 12 months post embolization</time_frame>
    <description>Quality of Life is scored using Moorehead-Ardelt II Quality of life questionnaire. The questionnaire involves 6 questions scored from -0,5 to +0,5. The mean of the 6 answers leads to a sum between -3 (very poor quality of life) to +3 (very good quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of upper digestive endoscopies</measure>
    <time_frame>12 months after bariatric embolization</time_frame>
    <description>Count of upper digestive endoscopies performed per patient during the study period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing embolization of the gastro-epiploic arcade</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Emblization of the gastro-epiploic arcade</intervention_name>
    <description>Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient aged ≥18 and ≤ 71 years old

          -  BMI ≥ 40 or BMI ≥ 35 in association with one of the following comorbidities:
             hypertension, type 2 diabetes, obstructive sleep apnea

          -  Relative contraindication to bariatric surgery

          -  Able to sign informed consent.

        Exclusion Criteria:

        General

          -  Impossible or unwilling to attend follow-up visits.

          -  Weight &gt; 250kg (weight limit of angiography table)

          -  Confirmed allergy to intravenous contrast agents.

          -  Pregnancy, breast feeding or willingness to conceive during the following year

          -  Impossible to maintain dorsal decubitus during intervention

          -  Life expectancy &lt; 1 year

          -  Current enrollment in another clinical trial

          -  Arterial anatomy rendering embolization very difficult or impossible (as evaluated by
             investigators)

          -  Patient under the protection of justice

          -  Patient under guardianship or trusteeship

        Gastro-intestinal

          -  Pre-existing chronic abdominal pain

          -  History of inflammatory bowel disease

          -  History of gastroparesis

          -  History of gastric surgery, gastric embolization or radiotherapy

          -  History of peptic ulcer

          -  Significant risk factors for peptic ulcer, including daily use of non-steroidal
             anti-inflammatory drugs, active smoking or active infection with Helicobacter pylori

          -  Abnormal upper digestive endoscopy

        Hepatic

          -  Cirrhosis

          -  Portal venous hypertension

          -  Bilirubin &gt; 2,0 mg/dL

          -  Albumin &lt; 2,5 g/L

        Cardiovascular

          -  Known aortic pathology i.e. aneurysm or dissection

          -  Severe peripheral arterial disease

        Renal

        - Renal failure, Creatinine Clearance &lt; 60ml/min/1,73 m2

        Hematologic/Immunologic/Oncologic/Infectious

          -  Acute or chronic infection

          -  Active cancer

          -  Auto-immune disease requiring immunosuppression

          -  Neutrophil count &lt; 1,5 x 10 ^ 9/L

          -  Platelet count &lt; 100 x 10 ^ 9/L

        Contraindication to contrast medium Visipaque solution for injection

          -  Hypersensitivity to the active substance (Iodixanol) or to any of the excipients

          -  History of immediate major or delayed skin reaction to the injection of the product

          -  Decompensated heart failure

          -  Thyrotoxicosis

          -  Contraindication to the use of the embogold microsphere
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raoul POP, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Neuroradiologie Interventionnelle, Nouvel Hôpital Civil, Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armelle TAKEDA, PhD</last_name>
    <phone>+33 390413608</phone>
    <email>armelle.takeda@ihu-strasbourg.eu</email>
  </overall_contact>
  <link>
    <url>https://www.cdc.gov/obesity/data/adult.html</url>
    <description>Centers for Disease Control and Prevention. Adult obesity facts.</description>
  </link>
  <reference>
    <citation>Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008 May 28;299(20):2401-5. doi: 10.1001/jama.299.20.2401.</citation>
    <PMID>18505949</PMID>
  </reference>
  <reference>
    <citation>Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007 Jul;121(7):492-6. Epub 2007 Mar 30.</citation>
    <PMID>17399752</PMID>
  </reference>
  <reference>
    <citation>Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014 Aug 8;(8):CD003641. doi: 10.1002/14651858.CD003641.pub4. Review.</citation>
    <PMID>25105982</PMID>
  </reference>
  <reference>
    <citation>Baptista V, Wassef W. Bariatric procedures: an update on techniques, outcomes and complications. Curr Opin Gastroenterol. 2013 Nov;29(6):684-93. doi: 10.1097/MOG.0b013e3283651af2. Review.</citation>
    <PMID>24100715</PMID>
  </reference>
  <reference>
    <citation>Aina R, Oliva VL, Therasse E, Perreault P, Bui BT, Dufresne MP, Soulez G. Arterial embolotherapy for upper gastrointestinal hemorrhage: outcome assessment. J Vasc Interv Radiol. 2001 Feb;12(2):195-200.</citation>
    <PMID>11265883</PMID>
  </reference>
  <reference>
    <citation>De Wispelaere JF, De Ronde T, Trigaux JP, de Cannière L, De Geeter T. Duodenal ulcer hemorrhage treated by embolization: results in 28 patients. Acta Gastroenterol Belg. 2002 Jan-Mar;65(1):6-11.</citation>
    <PMID>12014319</PMID>
  </reference>
  <reference>
    <citation>Defreyne L, Vanlangenhove P, De Vos M, Pattyn P, Van Maele G, Decruyenaere J, Troisi R, Kunnen M. Embolization as a first approach with endoscopically unmanageable acute nonvariceal gastrointestinal hemorrhage. Radiology. 2001 Mar;218(3):739-48.</citation>
    <PMID>11230648</PMID>
  </reference>
  <reference>
    <citation>Goldman ML, LAND WC, Bradley EL, Anderson RT. Transcatheter therapeutic embolization in the management of massive upper gastrointestinal bleeding. Radiology. 1976 Sep;120(3):513-21.</citation>
    <PMID>1085008</PMID>
  </reference>
  <reference>
    <citation>Holme JB, Nielsen DT, Funch-Jensen P, Mortensen FV. Transcatheter arterial embolization in patients with bleeding duodenal ulcer: an alternative to surgery. Acta Radiol. 2006 Apr;47(3):244-7.</citation>
    <PMID>16613304</PMID>
  </reference>
  <reference>
    <citation>Lang EV, Picus D, Marx MV, Hicks ME. Massive arterial hemorrhage from the stomach and lower esophagus: impact of embolotherapy on survival. Radiology. 1990 Oct;177(1):249-52.</citation>
    <PMID>2399325</PMID>
  </reference>
  <reference>
    <citation>Lieberman DA, Keller FS, Katon RM, Rosch J. Arterial embolization for massive upper gastrointestinal tract bleeding in poor surgical candidates. Gastroenterology. 1984 May;86(5 Pt 1):876-85.</citation>
    <PMID>6608465</PMID>
  </reference>
  <reference>
    <citation>Ljungdahl M, Eriksson LG, Nyman R, Gustavsson S. Arterial embolisation in management of massive bleeding from gastric and duodenal ulcers. Eur J Surg. 2002;168(7):384-90.</citation>
    <PMID>12463427</PMID>
  </reference>
  <reference>
    <citation>Miller M Jr, Smith TP. Angiographic diagnosis and endovascular management of nonvariceal gastrointestinal hemorrhage. Gastroenterol Clin North Am. 2005 Dec;34(4):735-52.</citation>
    <PMID>16303580</PMID>
  </reference>
  <reference>
    <citation>Morris DC, Nichols DM, Connell DG, Burhenne HJ. Embolization of the left gastric artery in the absence of angiographic extravasation. Cardiovasc Intervent Radiol. 1986;9(4):195-8.</citation>
    <PMID>3094950</PMID>
  </reference>
  <reference>
    <citation>Ripoll C, Bañares R, Beceiro I, Menchén P, Catalina MV, Echenagusia A, Turegano F. Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol. 2004 May;15(5):447-50.</citation>
    <PMID>15126653</PMID>
  </reference>
  <reference>
    <citation>Rösch J, Dotter CT, Brown MJ. Selective arterial embolization. A new method for control of acute gastrointestinal bleeding. Radiology. 1972 Feb;102(2):303-6.</citation>
    <PMID>4536688</PMID>
  </reference>
  <reference>
    <citation>Schenker MP, Duszak R Jr, Soulen MC, Smith KP, Baum RA, Cope C, Freiman DB, Roberts DA, Shlansky-Goldberg RD. Upper gastrointestinal hemorrhage and transcatheter embolotherapy: clinical and technical factors impacting success and survival. J Vasc Interv Radiol. 2001 Nov;12(11):1263-71.</citation>
    <PMID>11698624</PMID>
  </reference>
  <reference>
    <citation>Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, Suga T. Transcatheter arterial embolization for massive bleeding from duodenal ulcers not controlled by endoscopic hemostasis. Endoscopy. 1995 May;27(4):304-7.</citation>
    <PMID>7555935</PMID>
  </reference>
  <reference>
    <citation>Kipshidze N, Archvadze A, Bertog S, Leon MB, Sievert H. Endovascular Bariatrics: First in Humans Study of Gastric Artery Embolization for Weight Loss. JACC Cardiovasc Interv. 2015 Oct;8(12):1641-4. doi: 10.1016/j.jcin.2015.07.016.</citation>
    <PMID>26493259</PMID>
  </reference>
  <reference>
    <citation>Syed MI, Morar K, Shaikh A, Craig P, Khan O, Patel S, Khabiri H. Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically (GET LEAN): Six-Month Preliminary Data. J Vasc Interv Radiol. 2016 Oct;27(10):1502-8. doi: 10.1016/j.jvir.2016.07.010. Epub 2016 Aug 24.</citation>
    <PMID>27567998</PMID>
  </reference>
  <reference>
    <citation>Weiss CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A. Clinical Safety of Bariatric Arterial Embolization: Preliminary Results of the BEAT Obesity Trial. Radiology. 2017 May;283(2):598-608. doi: 10.1148/radiol.2016160914. Epub 2017 Feb 14.</citation>
    <PMID>28195823</PMID>
  </reference>
  <reference>
    <citation>Bai ZB, Qin YL, Deng G, Zhao GF, Zhong BY, Teng GJ. Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients. Obes Surg. 2018 Apr;28(4):907-915. doi: 10.1007/s11695-017-2979-9.</citation>
    <PMID>29063494</PMID>
  </reference>
  <reference>
    <citation>Pirlet C, Ruzsa Z, Costerousse O, Nemes B, Merkely B, Poirier P, Bertrand OF. Transradial left gastric artery embolization to treat severe obesity: A pilot study. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):365-370. doi: 10.1002/ccd.27846. Epub 2018 Oct 4.</citation>
    <PMID>30286527</PMID>
  </reference>
  <reference>
    <citation>Elens S, Roger T, Elens M, Rommens J, Sarafidis A, Capelluto E, Delcour C. Gastric Embolization as Treatment for Overweight Patients; Efficacy and Safety. Cardiovasc Intervent Radiol. 2019 Apr;42(4):513-519. doi: 10.1007/s00270-018-2130-x. Epub 2018 Nov 28.</citation>
    <PMID>30488305</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric embolization</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

